R252
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 91
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.570
- INTERFERON_GAMMA_RESPONSE+0.560
- ALLOGRAFT_REJECTION+0.540
- COMPLEMENT+0.420
- INFLAMMATORY_RESPONSE+0.390
- KRAS_SIGNALING_UP+0.380
- IL6_JAK_STAT3_SIGNALING+0.370
- IL2_STAT5_SIGNALING+0.340
- G2M_CHECKPOINT+0.320
- TNFA_SIGNALING_VIA_NFKB+0.320
Top 10 suppressed
- PEROXISOME-0.280
- ADIPOGENESIS-0.250
- FATTY_ACID_METABOLISM-0.220
- OXIDATIVE_PHOSPHORYLATION-0.220
- PROTEIN_SECRETION-0.200
- GLYCOLYSIS-0.180
- DNA_REPAIR-0.160
- WNT_BETA_CATENIN_SIGNALING-0.160
- BILE_ACID_METABOLISM-0.110
- UNFOLDED_PROTEIN_RESPONSE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-21-1070-01A-01R-0692-07 | — | cohortSQ1 | 0.864 |
| 2 | 4ff81b7f-2dbc-453f-a68b-fe40315b2ef7 | — | — | 0.862 |
| 3 | MNG943 | — | — | 0.859 |
| 4 | TCGA-BT-A42E-01A-11R-A23W-07 | — | — | 0.856 |
| 5 | TCGA-A2-A0ST-01A-12R-A084-07 | — | D | 0.854 |
| 6 | SRR10842366 | — | — | 0.850 |
| 7 | SRR1516078 | — | — | 0.846 |
| 8 | 346fe4c0-2ea0-45b4-8863-b0f9e7756ad6 | — | — | 0.845 |
| 9 | SRR8613765 | — | D | 0.838 |
| 10 | R317 | — | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |